NCE-1 Intelligence & Market Opportunity

Paxlovid

Nirmatrelvir And Ritonavir

Antiviral

Tablet

Paxlovid is an oral treatment for mild to moderate COVID-19 in high-risk patients. It stops the virus from multiplying and helps prevent severe illness when taken early.

Approval Date

25-May-23

NCE-1 Date

25-May-27

NCE Date

25-May-28

Commercial snapshot

Market performance & projections

Revenue ($M)

2362

CAGR (%)

-0.0253

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2271

2027

2237

2028

2126

2029

2132

2030

2089

2031

2047

2032

2014

Molecule profile

Details & specifications

Molecule

Nirmatrelvir And Ritonavir

Innovator

PFIZER INC

Dosage Form

Tablet

Strength

150 mg; 100 mg; 300 mg; 100 mg

Therapeutic Category

Antiviral

Usage

To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.